Travere Therapeutics (TVTX)

Executive Summary

Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with a lead product, sparsentan (FILSPARI), approved for IgA nephropathy (IgAN) and undergoing clinical development for additional indications such as focal segmental glomerulosclerosis (FSGS) and ANCA vasculitis. The company also has pegtibatinase in Phase 3 for homocystinuria, a rare metabolic disorder. Despite recent turbulence from mixed clinical data and competitive pressure in IgAN, Travere's pipeline holds potential for label expansion and new approvals. The company's late-stage assets and ongoing pivotal trials position it for significant catalysts in the near term, though execution risk remains.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 topline data for sparsentan in FSGS (DUPLEX study)60% success
• Q3 2026FDA decision on pegtibatinase for homocystinuria (based on Phase 3 data)70% success
• Q4 2026Phase 2 data for sparsentan in ANCA-associated vasculitis50% success